Home » Topics » BioWorld Science

BioWorld Science
RSS

Dura obtains marketing rights of Lilly's cephalosporin antibiotics

Aug. 30, 1996

ADCON-L and ADCON-T/N research demonstrates efficacy

Aug. 30, 1996

Treatment for keratinization disorders described by Janssen

Aug. 30, 1996

Sepracoat given European Approval of Conformity Certificate

Aug. 30, 1996

Merck & Co. reports NK1 antagonists

Aug. 30, 1996

Lidocaine topical patch effective in treating post-herpetic neuralgia

Aug. 30, 1996

Novel antitumor compounds claimed by Kyorin/Sagami

Aug. 23, 1996

STV: Possible antituberculosis and autoimmune disease therapy

Aug. 23, 1996

Erythromycin A 9-O-oxime derivatives from Zambon

Aug. 23, 1996

Potential tachykinin NK1 antagonists from Merck & Co.

Aug. 23, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...